382 related articles for article (PubMed ID: 30400970)
1. Recommendations for the design of small population clinical trials.
Day S; Jonker AH; Lau LPL; Hilgers RD; Irony I; Larsson K; Roes KC; Stallard N
Orphanet J Rare Dis; 2018 Nov; 13(1):195. PubMed ID: 30400970
[TBL] [Abstract][Full Text] [Related]
2. A Global Approach to Rare Diseases Research and Orphan Products Development: The International Rare Diseases Research Consortium (IRDiRC).
Cutillo CM; Austin CP; Groft SC
Adv Exp Med Biol; 2017; 1031():349-369. PubMed ID: 29214582
[TBL] [Abstract][Full Text] [Related]
3. Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force.
Nabbout R; Zanello G; Baker D; Black L; Brambilla I; Buske OJ; Conklin LS; Davies EH; Julkowska D; Kim Y; Klopstock T; Nakamura H; Nielsen KG; Pariser AR; Pastor JC; Scarpa M; Smith M; Taruscio D; Groft S
Orphanet J Rare Dis; 2023 May; 18(1):109. PubMed ID: 37161573
[TBL] [Abstract][Full Text] [Related]
4. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.
Southall NT; Natarajan M; Lau LPL; Jonker AH; Deprez B; Guilliams T; Hunter L; Rademaker CM; Hivert V; Ardigò D;
Orphanet J Rare Dis; 2019 Oct; 14(1):225. PubMed ID: 31615551
[TBL] [Abstract][Full Text] [Related]
5. Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.
Hilgers RD; Bogdan M; Burman CF; Dette H; Karlsson M; König F; Male C; Mentré F; Molenberghs G; Senn S
Orphanet J Rare Dis; 2018 May; 13(1):77. PubMed ID: 29751809
[TBL] [Abstract][Full Text] [Related]
6. The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies.
Beaverson KL; Julkowska D; Letinturier MCV; Aartsma-Rus A; Austin J; Bueren J; Frost S; Hamamura M; Larkindale J; LaRosa G; Magenheim R; Merico A; Pasmooij AMG; Pirard V; Ekow Thomford N; Wada M; Wong-Rieger D; Hartman AL
Ther Adv Rare Dis; 2023; 4():26330040231188979. PubMed ID: 37529076
[TBL] [Abstract][Full Text] [Related]
7. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
8. An overview of the impact of rare disease characteristics on research methodology.
Whicher D; Philbin S; Aronson N
Orphanet J Rare Dis; 2018 Jan; 13(1):14. PubMed ID: 29351763
[TBL] [Abstract][Full Text] [Related]
9. Preparing for the Future of Rare Diseases.
Groft SC; Posada de la Paz M
Adv Exp Med Biol; 2017; 1031():641-648. PubMed ID: 29214596
[TBL] [Abstract][Full Text] [Related]
10. Challenges of developing and conducting clinical trials in rare disorders.
Kempf L; Goldsmith JC; Temple R
Am J Med Genet A; 2018 Apr; 176(4):773-783. PubMed ID: 28815894
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
13. The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact.
Lochmüller H; Torrent I Farnell J; Le Cam Y; Jonker AH; Lau LP; Baynam G; Kaufmann P; Dawkins HJ; Lasko P; Austin CP; Boycott KM;
Eur J Hum Genet; 2017 Dec; 25(12):1293-1302. PubMed ID: 29158551
[TBL] [Abstract][Full Text] [Related]
14. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
[TBL] [Abstract][Full Text] [Related]
15. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
16. Experimental designs for small randomised clinical trials: an algorithm for choice.
Cornu C; Kassai B; Fisch R; Chiron C; Alberti C; Guerrini R; Rosati A; Pons G; Tiddens H; Chabaud S; Caudri D; Ballot C; Kurbatova P; Castellan AC; Bajard A; Nony P; ; Aarons L; Bajard A; Ballot C; Bertrand Y; Bretz F; Caudri D; Castellan C; Chabaud S; Cornu C; Dufour F; Dunger-Baldauf C; Dupont JM; Fisch R; Guerrini R; Jullien V; Kassaï B; Nony P; Ogungbenro K; Pérol D; Pons G; Tiddens H; Rosati A; Alberti C; Chiron C; Kurbatova P; Nabbout R
Orphanet J Rare Dis; 2013 Mar; 8():48. PubMed ID: 23531234
[TBL] [Abstract][Full Text] [Related]
17. Directions for new developments on statistical design and analysis of small population group trials.
Hilgers RD; Roes K; Stallard N;
Orphanet J Rare Dis; 2016 Jun; 11(1):78. PubMed ID: 27301273
[TBL] [Abstract][Full Text] [Related]
18. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
19. The importance of international collaboration for rare diseases research: a European perspective.
Julkowska D; Austin CP; Cutillo CM; Gancberg D; Hager C; Halftermeyer J; Jonker AH; Lau LPL; Norstedt I; Rath A; Schuster R; Simelyte E; van Weely S
Gene Ther; 2017 Sep; 24(9):562-571. PubMed ID: 28440796
[TBL] [Abstract][Full Text] [Related]
20. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
Maeda K; Kaneko M; Narukawa M; Arato T
Orphanet J Rare Dis; 2017 Aug; 12(1):143. PubMed ID: 28835285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
